Plymouth, MN · Founded 2017 · Privately Held (backing)
Developer of a medical device system designed to improve metabolic function in individuals with diabetes by resetting metabolic signalling in the small intestine. Endogenex is based in Plymouth, MN and was founded in 2017. It was valued at $218 million at its later-stage round in Mar 2026, the last priced event on record. It has raised $190 million across 3 recorded rounds; the latest was a $69.6 million later-stage round in Jun 2024.
PMV mark · valuation
$218.0M
Oct 2026
Priced at
its later-stage round
Mar 2026
Total raised
$190.4M
Last round
Later Stage VC
Jun 2024
No prints on record
No secondary trades in Endogenex shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Endogenex with a free account
·The complete investor list: 11 names
·Watch Endogenex: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Endogenex stock.
